LivaNova PLC (LIVN) FY2025 10-K Annual Report
LivaNova PLC (LIVN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
LivaNova PLC FY2025 10-K Analysis
Business Overview
- • Core business model: Medical technology company with Cardiopulmonary and Neuromodulation segments driving revenue
- • New product emphasis: aura6000 System for treating Obstructive Sleep Apnea, increasing Neuromodulation R&D expense by $11.2M
- • Strategic shift: Reduced litigation provision for 3T Heater-Cooler device by $15.3M, improving Cardiopulmonary segment income
- • Quantitative metric: Net revenue up 10.7% to $1.39B; Cardiopulmonary revenue up 14.9%, Neuromodulation up 7.0% YoY
- • Noteworthy fact: $366M SNIA environmental liability expense recorded due to 2025 Italian Supreme Court ruling on joint liability
Management Discussion & Analysis
- • Revenue and YoY change not disclosed explicitly in provided text
- • No profitability or margin % figures available in text
- • No segment performance data provided
- • Cash flow, buybacks, dividends, capex details not included
- • Risks from FX volatility, inflation, geopolitical instability, supply chain challenges highlighted as key emerging risks
Risk Factors
- • Regulatory risk from 3T Heater-Cooler device litigation provision reducing cash outflows by $71.3M in 2025
- • Geopolitical risk from exposure to hospital and healthcare sectors across multiple countries affecting trade receivables concentration
- • Operational risk from increased investing activities $33.9M in plant, property, and software for manufacturing capacity expansion
- • Competitive risk from sale of Ceribell, Inc. investment for $6.5M indicating strategic shift or response to market
- • Financial risk from debt reduction $280.9M in 2025 lowered debt from $627.6M to $376.7M, decreasing leverage ratio from 47.5% to 31.4% equity
LivaNova PLC FY2025 Key Financial MetricsXBRL
Revenue
$1.4B
▲ +10.7% YoY
Net Income
-$242M
▼ -483.5% YoY
Gross Margin
67.7%
▼ -177bp YoY
Operating Margin
14.4%
▲ +407bp YoY
Net Margin
-17.5%
▼ -2251bp YoY
ROE
-20.2%
▼ -2500bp YoY
Total Assets
$2.6B
▲ +4.0% YoY
EPS (Diluted)
$-4.45
▼ -483.6% YoY
Operating Cash Flow
$254M
▲ +39.0% YoY
Source: XBRL data from LivaNova PLC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on LivaNova PLC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.